ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1345

Improving Pneumococcal Immunization Rates for Patients on Immunosuppressant Medications at an Academic Rheumatology Clinic

Lauren Dudley1, Stephen Liu2, Krista Merrihew1, Jocelyn Verrill1 and Lin Brown1, 1Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2Internal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Quality improvement and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Quality Measures and Quality of Care

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with rheumatologic diseases are frequently placed on immunosuppressant medications which increase their risk of developing Streptococcus pneumoniae infections.  The Advisory Committee on Immunization Practices recommends that all immunosuppressed adults receive the 13-valent pneumococcal conjugate vaccine (PCV-13) followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV-23) but many specialty clinics lack processes of care that facilitate immunization.  The objective of this study was to improve pneumococcal immunization rates for patients on immunosuppressant medications in the adult rheumatology clinic.

Methods:   Immunization rates for PCV-13 and PPSV-23 were defined as the proportion of visits in which patients were up to date on their immunization.  Data obtained from the electronic health record from May 2011 to April 2014 was analyzed using statistical process control methods.  Rates over time were tracked using p-charts.  Semi-structured interviews were performed with clinic staff to map the processes for immunization and create cause-and-effect diagrams.   Interventions consisted of staff and provider education, a standardized process for obtaining immunization histories and a standing order permitting clinical support staff to order and administer immunizations via a protocol.

Results:   At baseline, there was no standardized process for assessing immunization histories or providing immunizations in the clinic.  Barriers included provider knowledge gaps, uncertainty regarding whether specialists or primary care providers should immunize, missing immunization records, lack of reminders and lack of time.   The interventions resulted in statistically significant increases in the PCV-13 immunization rate from 3.0% to 33.3% (p-value < 0.001) and the PPSV-23 immunization rate from 58.1% to 64.9% (p-value < 0.001).

Conclusion:   Rheumatologists place many patients on immunosuppressant medications rendering them high risk for infection yet many clinics have not incorporated immunizations into their standard processes.  Standing orders combined with education should be considered as a potential intervention.


Disclosure:

L. Dudley,
None;

S. Liu,
None;

K. Merrihew,
None;

J. Verrill,
None;

L. Brown,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-pneumococcal-immunization-rates-for-patients-on-immunosuppressant-medications-at-an-academic-rheumatology-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology